L Lai Lab · 賴峻毅實驗室
News & updates

Lately,
in the lab.

Conference posters, manuscript milestones, talks, lab life, and the occasional grant. The most recent and most relevant sits up top.

Pinned Phase III · postMONARCH

The headline story.

Phase III trial · JCO

postMONARCH results published in the Journal of Clinical Oncology.

The Phase III postMONARCH trial established abemaciclib plus fulvestrant as a treatment option for advanced breast cancer patients who have progressed on prior CDK4/6 inhibition. Dr. Lai is a co-author on the international team led by Dr. Kalinsky.

Dec 2024 J Clin Oncol · 10.1200/JCO-24-02086
Read in Publications
JCO
2024 Phase III · postMONARCH
2025 Current
Feb 2025
HDAC inhibitors modulate Hippo pathway signaling in HR+ breast cancer — accepted, Clinical Epigenetics.
Lin TI et al. demonstrate that HDAC inhibition engages the Hippo pathway in a context-dependent manner in hormone-positive breast cancer cells.
Jan 2025
Real-world outcomes in metastatic prostate neuroendocrine carcinoma — JCMA.
A retrospective analysis of genomic and clinical features in a treatment-refractory patient group.
2025
We are recruiting. PhD students & postdocs welcome.
Interested in chemical biology, proteomics, or precision oncology? Get in touch — see open positions below.
jilai@nycu.edu.tw →
2024 3 entries
Dec 2024
postMONARCH Phase III results published — Journal of Clinical Oncology.
Abemaciclib + fulvestrant after progression on CDK4/6 inhibition. International consortium publication.
2024
Lab presentations at multiple Taiwan Oncology Society meetings.
CDK7 / Hippo data and CDK6 proximity proteomics results.
2024
New trainees join the lab.
The team expanded with new master's and PhD students across all three research programs.
2023 4 entries
Nov 2023
Palbociclib-associated neutropenia in Asian patients — The Oncologist.
First clinical and genotypic analysis explaining the higher prevalence of neutropenia in Asian cohorts.
Apr 2023
AACR Annual Meeting 2023 — Orlando, FL.
Poster presentation: CDK7 inhibition modulates CDK4/6 inhibitor resistance through the Hippo pathway. Our first major international showing of this work.
Download poster (PDF) →
Jun 2023
Lab group photo — summer 2023.
The whole team together. See it on the People page.
Dec 2023
Proximity-labeling proteomics manuscript submitted.
Chung WT et al. — 14-3-3 protein YWHAB identified as a mediator of CDK4/6 inhibitor resistance. Under revision.
2022 2 entries
Oct 2022
A systemic review of taxanes — Frontiers in Oncology.
A comprehensive overview of taxane biology and side-effect profiles in metastatic breast cancer.
Sep 2022
IKZF3 amplification as a therapeutic target in HER2+ breast cancer.
Lin CY et al., Medical Oncology — characterization of a recurrent amplification with druggability implications.
2019 Lab founded
2019
Lai Lab founded at NYCU.
Dr. Jiun-I Lai joined the Institute of Clinical Medicine as Assistant Professor, establishing the lab's focus on hormone-positive breast cancer biology and CDK4/6 inhibitor resistance.
Open positions

We're looking for the next person to join the lab.

If you're a graduate student, postdoc, or research associate with interest in cancer biology, chemical biology, or precision oncology — let's talk.

Email Dr. Lai
PhD student · Institute of Clinical Medicine Open
Master's student · breast cancer biology Open
Postdoctoral researcher · chemical biology Open
Research associate · proteomics Open
Medical student rotations By inquiry
In partnership with NYCU · Taipei Veterans General Hospital · Comprehensive Breast Health Center